<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193244</url>
  </required_header>
  <id_info>
    <org_study_id>C21004</org_study_id>
    <secondary_id>2010-018661-35</secondary_id>
    <secondary_id>0991413276</secondary_id>
    <secondary_id>10/H0406/75</secondary_id>
    <secondary_id>U1111-1181-0387</secondary_id>
    <nct_id>NCT01193244</nct_id>
  </id_info>
  <brief_title>Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700)
      plus prednisone compared with placebo plus prednisone in the treatment of men with
      progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2010</start_date>
  <completion_date type="Actual">April 7, 2016</completion_date>
  <primary_completion_date type="Actual">January 1, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Progression-free Survival (rPFS)</measure>
    <time_frame>Baseline until radiographic disease progression or death, whichever occurred first (approximately up to 4.7 years)</time_frame>
    <description>rPFS was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause, whichever occurred first. Radiographic disease progression was evaluated by computerized tomography (CT) scan or magnetic resonance imaging (MRI) and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for soft tissue disease and Prostate Cancer Working Group (PCWG2) guidelines for bone disease. Participants who did not reach the endpoint were censored at their last assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline until death (up to 4.7 years)</time_frame>
    <description>Overall survival was calculated from the date of participant randomization to the date of participant death due to any cause. Participants without documentation of death at time of the analysis were censored as of the date the participant was last known to be alive, or the data cutoff date, whichever was earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 50 Percent Reduction From Baseline in Prostate Specific Antigen (PSA50) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PSA50 is defined as a decline of at least 50 percent (%) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Favorable Circulating Tumor Cell Count (CTC) Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>A favorable CTC count was defined as less than &lt;5 counts per 7.5 milliliter (mL) in whole blood. An unfavorable CTC count was defined as greater than or equal to (&gt;=) 5 counts/7.5 mL in whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Progression</measure>
    <time_frame>Baseline until End of treatment (EOT) (approximately up to 4.7 years)</time_frame>
    <description>Time to pain progression was defined as the time from participant randomization to the first assessment date of pain progression. Pain progression was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: The brief pain inventory-short form (BPI-SF) worst pain score was &gt;=4 with a &gt;=2 point increase over baseline in BPI-SF worst pain score with stable or increased analgesic use; The BPI-SF worst pain score was &gt;=4 but not less than baseline with new or increased (relative to baseline) Step II or Step III analgesic use; The BPI-SF worst pain score was &lt;=3 but not less than baseline with new or increased (relative to baseline) Step III analgesic use. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 100 with lower scores being indicative of less pain or pain interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to (&gt;=) Grade 3</measure>
    <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
    <description>Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Related to Vital Signs</measure>
    <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Related to Weight</measure>
    <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Worst Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>Baseline until EOT (approximately up to 4.7 years)</time_frame>
    <description>ECOG assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (&gt;50 percent of waking hours [hrs]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair &gt;50 percent of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. Worst change was defined as the worst overall change that occurred in ECOG status at any measured time point during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to EOT (Cycle 61 Day 58)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Change From Baseline Over Time in Cardiac Ejection Fraction</measure>
    <time_frame>Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)</time_frame>
    <description>Worst change was defined as the worst overall change that occurred in cardiac ejection fraction at any measured time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Categorized Into Investigations Related to Chemistry, Hematology or Coagulation</measure>
    <time_frame>Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Skeletal Related Events (SRE)</measure>
    <time_frame>Baseline up to EOT (approximately up to 4.7 years)</time_frame>
    <description>Skeletal related (SRE) event is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to SRE</measure>
    <time_frame>Baseline up to EOT (Cycle 61 Day 58)</time_frame>
    <description>Time to SRE is defined as the time from randomization to SRE, or death due to any cause, whichever comes first. SRE is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PSA50 Response at Any Time During the Study</measure>
    <time_frame>Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37</time_frame>
    <description>The PSA50 is defined as a decline of PSA by 50 percent from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 90 Percent Reduction From Baseline in Prostate Specific Antigen (PSA90 Response) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PSA90 is defined as a decline of PSA by 90 percent from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PSA90 Response at Any Time During the Study</measure>
    <time_frame>Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37</time_frame>
    <description>The PSA90 is defined as a decline of PSA by 90 percent from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>Baseline until the final on treatment assessment or until end of short term follow-up following discontinuation of treatment, whichever occurred later (approximately up to 4.7 years)</time_frame>
    <description>Time to PSA progression was defined as time from randomization to a PSA increase of 25 percent and PSA rise of at least 2 nanogram per milliliter (ng/mL) above the lowest value observed post baseline or, if no PSA decline occurred post baseline, compared to baseline PSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Docetaxel Chemotherapy</measure>
    <time_frame>Baseline until start of docetaxel chemotherapy (up to 4.7 years)</time_frame>
    <description>Time to docetaxel based chemotherapy is defined as the time from randomization to the start of docetaxel based chemotherapy for prostate cancer, regardless of whether the participant received concurrent orteronel or not. Deaths due to disease progression prior to Docetaxel based chemotherapy were considered as events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Subsequent Antineoplastic Therapy</measure>
    <time_frame>Baseline until start of subsequent antineoplastic therapy (up to 4.7 years)</time_frame>
    <description>Time to subsequent antineoplastic therapy is defined as the time from randomization to the start of any alternate antineoplastic therapy for prostate cancer. Deaths due to disease progression prior to antineoplastic therapy for prostate cancer are considered as events. Otherwise, time to next therapy is censored at the date of death or the last date the participant was known to be alive or the data cutoff date, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response</measure>
    <time_frame>Baseline until disease progression or death, whichever occurred first (approximately up to 4.7 years)</time_frame>
    <description>Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. A CR was defined as the disappearance of all target lesions determined by computerized tomography (CT) or MRI. Any pathological lymph nodes (whether target or non-target) must have had reduction in short axis to &lt;10 millimetre (mm). A PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of longest diameters of non-lymph node lesions and of the short diameter or short axis of lymph nodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Global Health Status</measure>
    <time_frame>Baseline until EOT (approximately up to 4.7 years)</time_frame>
    <description>Global health status deterioration is defined as a drop greater than 16 points from the baseline assessment, confirmed at least 3 weeks later, on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module 30 (EORTC QLQ-C30) index after the score has been linearly transformed to a 0 to 100 scale. EORTC QLQ-C30 consists of 30 questions, where question 1 to 28 can be answered with 1: Not at all, 2: A little, 3: Quite a bit, 4: Very much and question 29 to 30 with 1: Very poor to 7: Excellent. For subscales a high score from 0-100 indicates: high global quality of life, high level of functioning (physical, role, emotional, cognitive, social) or a high level of symptoms (fatigue, nausea, pain, dyspnea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1560</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Orteronel + prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + prednisone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orteronel</intervention_name>
    <description>Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of &lt;50 ng/dL.</description>
    <arm_group_label>Orteronel + prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of &lt;50 ng/dL.</description>
    <arm_group_label>Placebo + prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of &lt;50 ng/dL.</description>
    <arm_group_label>Orteronel + prednisone</arm_group_label>
    <arm_group_label>Placebo + prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet all of the following inclusion criteria:

          -  Voluntary written consent

          -  Male patients 18 years or older

          -  Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma

          -  Radiograph-documented metastatic disease

          -  Progressive disease

          -  Prior surgical castration or concurrent use of an agent for medical castration

          -  Either absence of pain or pain not requiring use of any opioid or narcotic analgesia
             in the 2 weeks prior to study entry

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Even if surgically sterilized, patients must practice effective barrier contraception
             during the entire study treatment and for 4 months after the last dose of study drug,
             OR abstain from heterosexual intercourse

          -  Meet screening laboratory values as specified in protocol

          -  Stable medical condition

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Known hypersensitivity to orteronel, prednisone or gonadotropin-releasing hormone
             (GnRH) analogue

          -  Received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone

          -  Received antiandrogen therapy within 6 weeks for bicalutamide and 4 weeks for all
             others prior to first dose of study drug

          -  Continuous daily use of oral prednisone or oral dexamethasone for more than 14 days
             within 3 months prior to study

          -  Received prior chemotherapy for prostate cancer with exception of neoadjuvant/adjuvant
             therapy as part of initial primary treatment for local disease that was completed 2 or
             more years prior to screening

          -  Exposure to radioisotope therapy within 4 weeks of receiving first dose of study drug;
             exposure to external beam radiation within 2 weeks of start of screening until
             receiving the first dose of study drug

          -  Documented central nervous system metastases

          -  Treatment with any investigational compound within 30 days prior to first dose of
             study drug

          -  Current spinal cord compression, bilateral hydronephrosis or current bladder neck
             outlet obstruction

          -  Diagnosis or treatment of another malignancy within 2 years preceding first dose of
             study drug except nonmelanoma skin cancer or in situ malignancy completely resected

          -  Uncontrolled cardiovascular condition as specified in study protocol

          -  Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C

          -  Unwilling or unable to comply with protocol

          -  Uncontrolled nausea, vomiting or diarrhea

          -  Known gastrointestinal disease or procedure that could interfere with oral absorption
             or tolerance of orteronel
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Highland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port St Lucie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corinth</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piitsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hobart</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurralta Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redcliffe</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wodonga</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bairro Nazare - Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barretos/sp</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caxias Do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza/ce</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ijui</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joinville</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lajeado - Rs</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piracicaba - Sp</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre- Rs</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre/rs</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ribeirao Preto - Sp</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro Rj</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Jose Do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Jose Dos Campos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba - Sp</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owen Sound</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Condes</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seinajoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 14</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kempen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nurtingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba-city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi-city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mito-city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakura City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimizucho Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suntou-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yamagata City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yufu-city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takapuna</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielsko-biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trencin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>April 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <disposition_first_submitted>March 4, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 4, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2016</disposition_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 324 investigative sites in North America, Europe, Australia, Brazil, Chile, Colombia, Hong Kong, Peru, Puerto Rico, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, and Taiwan from 19 October 2010 to 7 April 2016.</recruitment_details>
      <pre_assignment_details>Male participants who were chemotherapy-naive and had metastatic castration-resistant prostate cancer (mCRPC) with documented progressive metastatic disease were enrolled in 1 of 2 treatment groups to receive Orteronel 400 milligram (mg) + Prednisone 5 mg or Placebo + Prednisone 5 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + Prednisone 5 mg</title>
          <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>Orteronel 400 mg + Prednisone 5 mg</title>
          <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="779"/>
                <participants group_id="P2" count="781"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="770">Participants who continued to receive Placebo after unblinding.</participants>
                <participants group_id="P2" count="784">Participants randomized to receive Placebo but crossed-over to receive Orteronel after unblinding.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="391"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="388"/>
                <participants group_id="P2" count="390"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="278"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo + Prednisone 5 mg</title>
          <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>Orteronel 400 mg + Prednisone 5 mg</title>
          <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="779"/>
            <count group_id="B2" value="781"/>
            <count group_id="B3" value="1560"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="8.19"/>
                    <measurement group_id="B2" value="70.9" spread="8.26"/>
                    <measurement group_id="B3" value="71.0" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="779"/>
                    <measurement group_id="B2" value="781"/>
                    <measurement group_id="B3" value="1560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="672"/>
                    <measurement group_id="B2" value="669"/>
                    <measurement group_id="B3" value="1341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="670"/>
                    <measurement group_id="B2" value="685"/>
                    <measurement group_id="B3" value="1355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province Of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>Height data was available for 1558 participants as follows: n= 778, 780.</description>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.77" spread="7.485"/>
                    <measurement group_id="B2" value="173.26" spread="7.858"/>
                    <measurement group_id="B3" value="173.02" spread="7.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight data was available for 1559 participants as follows: n= 778, 781.</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.04" spread="15.846"/>
                    <measurement group_id="B2" value="85.09" spread="16.286"/>
                    <measurement group_id="B3" value="84.57" spread="16.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI data was available for 1557 participants as follows: n= 777, 780.</description>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.09" spread="4.651"/>
                    <measurement group_id="B2" value="28.28" spread="4.730"/>
                    <measurement group_id="B3" value="28.19" spread="4.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiographic Progression-free Survival (rPFS)</title>
        <description>rPFS was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause, whichever occurred first. Radiographic disease progression was evaluated by computerized tomography (CT) scan or magnetic resonance imaging (MRI) and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for soft tissue disease and Prostate Cancer Working Group (PCWG2) guidelines for bone disease. Participants who did not reach the endpoint were censored at their last assessment.</description>
        <time_frame>Baseline until radiographic disease progression or death, whichever occurred first (approximately up to 4.7 years)</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Progression-free Survival (rPFS)</title>
          <description>rPFS was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause, whichever occurred first. Radiographic disease progression was evaluated by computerized tomography (CT) scan or magnetic resonance imaging (MRI) and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for soft tissue disease and Prostate Cancer Working Group (PCWG2) guidelines for bone disease. Participants who did not reach the endpoint were censored at their last assessment.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="8.32" upper_limit="10.91"/>
                    <measurement group_id="O2" value="13.8" lower_limit="13.05" upper_limit="14.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on a stratified Coxs proportional hazard regression model with stratification factors of region and radiographic disease progression at baseline with treatment as a factor in the model. A hazard ratio less than (&lt;) 1 indicated better prevention of death in the orteronel group compared to the placebo group. From log-rank test stratified by region and radiographic disease progression at Baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.707</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.626</ci_lower_limit>
            <ci_upper_limit>0.799</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival was calculated from the date of participant randomization to the date of participant death due to any cause. Participants without documentation of death at time of the analysis were censored as of the date the participant was last known to be alive, or the data cutoff date, whichever was earlier.</description>
        <time_frame>Baseline until death (up to 4.7 years)</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was calculated from the date of participant randomization to the date of participant death due to any cause. Participants without documentation of death at time of the analysis were censored as of the date the participant was last known to be alive, or the data cutoff date, whichever was earlier.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="27.28" upper_limit="32.38"/>
                    <measurement group_id="O2" value="29.9" lower_limit="27.88" upper_limit="33.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on a stratified Coxs proportional hazard regression model with stratification factors of region and radiographic disease progression at baseline with treatment as a factor in the model. A hazard ratio &lt;1 indicated better prevention of death in the orteronel group compared to the placebo group. From log-rank test stratified by region and radiographic disease progression at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59755</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.963</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.838</ci_lower_limit>
            <ci_upper_limit>1.107</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 50 Percent Reduction From Baseline in Prostate Specific Antigen (PSA50) Response at Week 12</title>
        <description>The PSA50 is defined as a decline of at least 50 percent (%) from baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 50 Percent Reduction From Baseline in Prostate Specific Antigen (PSA50) Response at Week 12</title>
          <description>The PSA50 is defined as a decline of at least 50 percent (%) from baseline.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="21.7" upper_limit="27.8"/>
                    <measurement group_id="O2" value="42.6" lower_limit="39.1" upper_limit="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression model with prognostic factors: region; radiographic disease progression at baseline; age; race; baseline Eastern Cooperative Oncology Group (ECOG) score; Gleason score at initial diagnosis; baseline PSA, natural log scale; presence of visceral disease; alkaline phosphatase; lactate dehydrogenase; and hemoglobin. Odds ratio greater than (&gt;)1 favored orteronel. P-values tested for odds ratio equal to 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.724</ci_lower_limit>
            <ci_upper_limit>2.721</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Favorable Circulating Tumor Cell Count (CTC) Levels at Week 12</title>
        <description>A favorable CTC count was defined as less than &lt;5 counts per 7.5 milliliter (mL) in whole blood. An unfavorable CTC count was defined as greater than or equal to (&gt;=) 5 counts/7.5 mL in whole blood.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Favorable Circulating Tumor Cell Count (CTC) Levels at Week 12</title>
          <description>A favorable CTC count was defined as less than &lt;5 counts per 7.5 milliliter (mL) in whole blood. An unfavorable CTC count was defined as greater than or equal to (&gt;=) 5 counts/7.5 mL in whole blood.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="7.2" upper_limit="11.4"/>
                    <measurement group_id="O2" value="15.4" lower_limit="12.9" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression model with prognostic factors: region; radiographic disease progression at baseline; age; race; baseline ECOG score; Gleason score at initial diagnosis; baseline PSA, natural log scale; presence of visceral disease; alkaline phosphatase; lactate dehydrogenase; and hemoglobin. Odds ratio &gt; 1 favored orteronel. P-values tested for odds ratio equal to 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.712</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.235</ci_lower_limit>
            <ci_upper_limit>2.373</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pain Progression</title>
        <description>Time to pain progression was defined as the time from participant randomization to the first assessment date of pain progression. Pain progression was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: The brief pain inventory-short form (BPI-SF) worst pain score was &gt;=4 with a &gt;=2 point increase over baseline in BPI-SF worst pain score with stable or increased analgesic use; The BPI-SF worst pain score was &gt;=4 but not less than baseline with new or increased (relative to baseline) Step II or Step III analgesic use; The BPI-SF worst pain score was &lt;=3 but not less than baseline with new or increased (relative to baseline) Step III analgesic use. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 100 with lower scores being indicative of less pain or pain interference.</description>
        <time_frame>Baseline until End of treatment (EOT) (approximately up to 4.7 years)</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Progression</title>
          <description>Time to pain progression was defined as the time from participant randomization to the first assessment date of pain progression. Pain progression was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: The brief pain inventory-short form (BPI-SF) worst pain score was &gt;=4 with a &gt;=2 point increase over baseline in BPI-SF worst pain score with stable or increased analgesic use; The BPI-SF worst pain score was &gt;=4 but not less than baseline with new or increased (relative to baseline) Step II or Step III analgesic use; The BPI-SF worst pain score was &lt;=3 but not less than baseline with new or increased (relative to baseline) Step III analgesic use. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 100 with lower scores being indicative of less pain or pain interference.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median was not estimable due to low number of events in the arm.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="28.57">Median was not estimable due to low number of events in the arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on a stratified Coxs proportional hazard regression model with stratification factors of region and radiographic disease progression at baseline with treatment as a factor in the model. A hazard ratio less than (&lt;) 1 indicated better prevention of death in the orteronel group compared to the placebo group. From log-rank test stratified by region and radiographic disease progression at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33906</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.885</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.688</ci_lower_limit>
            <ci_upper_limit>1.138</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="733"/>
                    <measurement group_id="O2" value="769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O2" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to (&gt;=) Grade 3</title>
        <description>Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE.</description>
        <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to (&gt;=) Grade 3</title>
          <description>Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE.</description>
          <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 or higher TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                    <measurement group_id="O2" value="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 (Death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Related to Vital Signs</title>
        <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Vital Signs</title>
          <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Related to Weight</title>
        <time_frame>Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Weight</title>
          <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Worst Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status</title>
        <description>ECOG assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (&gt;50 percent of waking hours [hrs]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair &gt;50 percent of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. Worst change was defined as the worst overall change that occurred in ECOG status at any measured time point during the treatment period.</description>
        <time_frame>Baseline until EOT (approximately up to 4.7 years)</time_frame>
        <population>Safety population where baseline and post-baseline assessments were available. Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status</title>
          <description>ECOG assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (&gt;50 percent of waking hours [hrs]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair &gt;50 percent of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. Worst change was defined as the worst overall change that occurred in ECOG status at any measured time point during the treatment period.</description>
          <population>Safety population where baseline and post-baseline assessments were available. Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: 0; Overall: 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 0; Overall: 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 0; Overall: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 0; Overall: 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 0; Overall: 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1; Overall: 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1; Overall: 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1; Overall: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1; Overall: 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1; Overall: 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 2; Overall: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings</title>
        <time_frame>Baseline up to EOT (Cycle 61 Day 58)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings</title>
          <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Change From Baseline Over Time in Cardiac Ejection Fraction</title>
        <description>Worst change was defined as the worst overall change that occurred in cardiac ejection fraction at any measured time point.</description>
        <time_frame>Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)</time_frame>
        <population>Safety population where baseline and post-baseline assessments were available. Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Change From Baseline Over Time in Cardiac Ejection Fraction</title>
          <description>Worst change was defined as the worst overall change that occurred in cardiac ejection fraction at any measured time point.</description>
          <population>Safety population where baseline and post-baseline assessments were available. Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>percent ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="676"/>
                <count group_id="O2" value="670"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="6.93"/>
                    <measurement group_id="O2" value="-4.8" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Categorized Into Investigations Related to Chemistry, Hematology or Coagulation</title>
        <time_frame>Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Categorized Into Investigations Related to Chemistry, Hematology or Coagulation</title>
          <population>Safety population included all participants who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Skeletal Related Events (SRE)</title>
        <description>Skeletal related (SRE) event is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.</description>
        <time_frame>Baseline up to EOT (approximately up to 4.7 years)</time_frame>
        <population>The ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Skeletal Related Events (SRE)</title>
          <description>Skeletal related (SRE) event is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.</description>
          <population>The ITT population included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="8.8" upper_limit="13.3"/>
                    <measurement group_id="O2" value="8.6" lower_limit="6.7" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to SRE</title>
        <description>Time to SRE is defined as the time from randomization to SRE, or death due to any cause, whichever comes first. SRE is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.</description>
        <time_frame>Baseline up to EOT (Cycle 61 Day 58)</time_frame>
        <population>The ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to SRE</title>
          <description>Time to SRE is defined as the time from randomization to SRE, or death due to any cause, whichever comes first. SRE is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence.</description>
          <population>The ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="8.32" upper_limit="10.98"/>
                    <measurement group_id="O2" value="13.9" lower_limit="13.68" upper_limit="16.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PSA50 Response at Any Time During the Study</title>
        <description>The PSA50 is defined as a decline of PSA by 50 percent from baseline.</description>
        <time_frame>Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37</time_frame>
        <population>ITT population where baseline and post-baseline assessments were available. The ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PSA50 Response at Any Time During the Study</title>
          <description>The PSA50 is defined as a decline of PSA by 50 percent from baseline.</description>
          <population>ITT population where baseline and post-baseline assessments were available. The ITT population included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 (n= 687, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.09" lower_limit="24.76" upper_limit="31.62"/>
                    <measurement group_id="O2" value="49.70" lower_limit="45.86" upper_limit="53.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 (n= 541, 540)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.94" lower_limit="30.92" upper_limit="39.12"/>
                    <measurement group_id="O2" value="54.81" lower_limit="50.51" upper_limit="59.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 (n= 438, 450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.99" lower_limit="32.45" upper_limit="41.70"/>
                    <measurement group_id="O2" value="56.00" lower_limit="51.28" upper_limit="60.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 (n= 344, 382)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.21" lower_limit="32.09" upper_limit="42.56"/>
                    <measurement group_id="O2" value="53.14" lower_limit="48.00" upper_limit="58.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 (n= 286, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.27" lower_limit="28.78" upper_limit="40.08"/>
                    <measurement group_id="O2" value="54.13" lower_limit="48.33" upper_limit="59.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 (n= 228, 272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.72" lower_limit="31.41" upper_limit="44.36"/>
                    <measurement group_id="O2" value="52.94" lower_limit="46.82" upper_limit="59.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 (n= 184, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.15" lower_limit="26.40" upper_limit="40.46"/>
                    <measurement group_id="O2" value="54.03" lower_limit="47.05" upper_limit="60.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 25 (n= 109, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.78" lower_limit="26.83" upper_limit="45.53"/>
                    <measurement group_id="O2" value="46.22" lower_limit="37.04" upper_limit="55.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 28 (n= 67, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.78" lower_limit="32.60" upper_limit="57.42"/>
                    <measurement group_id="O2" value="48.05" lower_limit="36.52" upper_limit="59.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 31 (n= 35, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.29" lower_limit="19.13" upper_limit="52.21"/>
                    <measurement group_id="O2" value="48.72" lower_limit="32.42" upper_limit="65.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 34 (n= 22, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.36" lower_limit="17.20" upper_limit="59.34"/>
                    <measurement group_id="O2" value="38.89" lower_limit="17.30" upper_limit="64.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 37 (n= 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.43" lower_limit="29.04" upper_limit="96.33"/>
                    <measurement group_id="O2" value="40.00" lower_limit="5.27" upper_limit="85.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 90 Percent Reduction From Baseline in Prostate Specific Antigen (PSA90 Response) at Week 12</title>
        <description>The PSA90 is defined as a decline of PSA by 90 percent from baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 90 Percent Reduction From Baseline in Prostate Specific Antigen (PSA90 Response) at Week 12</title>
          <description>The PSA90 is defined as a decline of PSA by 90 percent from baseline.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PSA90 Response at Any Time During the Study</title>
        <description>The PSA90 is defined as a decline of PSA by 90 percent from baseline.</description>
        <time_frame>Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37</time_frame>
        <population>ITT population where baseline and post-baseline assessments were available. The ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PSA90 Response at Any Time During the Study</title>
          <description>The PSA90 is defined as a decline of PSA by 90 percent from baseline.</description>
          <population>ITT population where baseline and post-baseline assessments were available. The ITT population included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 (n= 687, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.39" lower_limit="3.82" upper_limit="7.35"/>
                    <measurement group_id="O2" value="16.67" lower_limit="13.93" upper_limit="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 (n= 541, 540)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.69" lower_limit="6.45" upper_limit="11.39"/>
                    <measurement group_id="O2" value="22.22" lower_limit="18.78" upper_limit="25.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 (n= 438, 450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.64" lower_limit="8.79" upper_limit="15.02"/>
                    <measurement group_id="O2" value="26.44" lower_limit="22.42" upper_limit="30.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 (n= 344, 382)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.79" lower_limit="9.45" upper_limit="16.79"/>
                    <measurement group_id="O2" value="26.18" lower_limit="21.84" upper_limit="30.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 (n= 286, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.24" lower_limit="8.67" upper_limit="16.61"/>
                    <measurement group_id="O2" value="25.74" lower_limit="20.91" upper_limit="31.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 (n= 228, 272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.72" lower_limit="8.69" upper_limit="17.75"/>
                    <measurement group_id="O2" value="26.10" lower_limit="20.99" upper_limit="31.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 (n= 184, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.87" lower_limit="6.77" upper_limit="16.29"/>
                    <measurement group_id="O2" value="28.44" lower_limit="22.45" upper_limit="35.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 25 (n= 109, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.01" lower_limit="5.82" upper_limit="18.44"/>
                    <measurement group_id="O2" value="21.01" lower_limit="14.08" upper_limit="29.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 28 (n= 67, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.42" lower_limit="8.49" upper_limit="27.48"/>
                    <measurement group_id="O2" value="27.27" lower_limit="17.74" upper_limit="38.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 31 (n= 35, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" lower_limit="1.80" upper_limit="23.06"/>
                    <measurement group_id="O2" value="12.82" lower_limit="4.30" upper_limit="27.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 34 (n= 22, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" lower_limit="0.12" upper_limit="22.84"/>
                    <measurement group_id="O2" value="22.22" lower_limit="6.41" upper_limit="47.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 37 (n= 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.29" lower_limit="0.36" upper_limit="57.87"/>
                    <measurement group_id="O2" value="20.00" lower_limit="0.51" upper_limit="71.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression</title>
        <description>Time to PSA progression was defined as time from randomization to a PSA increase of 25 percent and PSA rise of at least 2 nanogram per milliliter (ng/mL) above the lowest value observed post baseline or, if no PSA decline occurred post baseline, compared to baseline PSA.</description>
        <time_frame>Baseline until the final on treatment assessment or until end of short term follow-up following discontinuation of treatment, whichever occurred later (approximately up to 4.7 years)</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression</title>
          <description>Time to PSA progression was defined as time from randomization to a PSA increase of 25 percent and PSA rise of at least 2 nanogram per milliliter (ng/mL) above the lowest value observed post baseline or, if no PSA decline occurred post baseline, compared to baseline PSA.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" lower_limit="5.56" upper_limit="5.59"/>
                    <measurement group_id="O2" value="8.3" lower_limit="8.28" upper_limit="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Docetaxel Chemotherapy</title>
        <description>Time to docetaxel based chemotherapy is defined as the time from randomization to the start of docetaxel based chemotherapy for prostate cancer, regardless of whether the participant received concurrent orteronel or not. Deaths due to disease progression prior to Docetaxel based chemotherapy were considered as events.</description>
        <time_frame>Baseline until start of docetaxel chemotherapy (up to 4.7 years)</time_frame>
        <population>ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Docetaxel Chemotherapy</title>
          <description>Time to docetaxel based chemotherapy is defined as the time from randomization to the start of docetaxel based chemotherapy for prostate cancer, regardless of whether the participant received concurrent orteronel or not. Deaths due to disease progression prior to Docetaxel based chemotherapy were considered as events.</description>
          <population>ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="16.44" upper_limit="21.43"/>
                    <measurement group_id="O2" value="23.0" lower_limit="20.71" upper_limit="24.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Subsequent Antineoplastic Therapy</title>
        <description>Time to subsequent antineoplastic therapy is defined as the time from randomization to the start of any alternate antineoplastic therapy for prostate cancer. Deaths due to disease progression prior to antineoplastic therapy for prostate cancer are considered as events. Otherwise, time to next therapy is censored at the date of death or the last date the participant was known to be alive or the data cutoff date, whichever is earlier.</description>
        <time_frame>Baseline until start of subsequent antineoplastic therapy (up to 4.7 years)</time_frame>
        <population>The ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Subsequent Antineoplastic Therapy</title>
          <description>Time to subsequent antineoplastic therapy is defined as the time from randomization to the start of any alternate antineoplastic therapy for prostate cancer. Deaths due to disease progression prior to antineoplastic therapy for prostate cancer are considered as events. Otherwise, time to next therapy is censored at the date of death or the last date the participant was known to be alive or the data cutoff date, whichever is earlier.</description>
          <population>The ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="12.16" upper_limit="14.86"/>
                    <measurement group_id="O2" value="17.2" lower_limit="15.09" upper_limit="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response</title>
        <description>Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. A CR was defined as the disappearance of all target lesions determined by computerized tomography (CT) or MRI. Any pathological lymph nodes (whether target or non-target) must have had reduction in short axis to &lt;10 millimetre (mm). A PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of longest diameters of non-lymph node lesions and of the short diameter or short axis of lymph nodes.</description>
        <time_frame>Baseline until disease progression or death, whichever occurred first (approximately up to 4.7 years)</time_frame>
        <population>The Response Evaluation Criteria in Solid Tumors (RECIST) evaluable population included all participants who had measurable disease by RECIST 1.1 at the baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response</title>
          <description>Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. A CR was defined as the disappearance of all target lesions determined by computerized tomography (CT) or MRI. Any pathological lymph nodes (whether target or non-target) must have had reduction in short axis to &lt;10 millimetre (mm). A PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of longest diameters of non-lymph node lesions and of the short diameter or short axis of lymph nodes.</description>
          <population>The Response Evaluation Criteria in Solid Tumors (RECIST) evaluable population included all participants who had measurable disease by RECIST 1.1 at the baseline assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="11.0" upper_limit="20.4"/>
                    <measurement group_id="O2" value="34.7" lower_limit="28.7" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration in Global Health Status</title>
        <description>Global health status deterioration is defined as a drop greater than 16 points from the baseline assessment, confirmed at least 3 weeks later, on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module 30 (EORTC QLQ-C30) index after the score has been linearly transformed to a 0 to 100 scale. EORTC QLQ-C30 consists of 30 questions, where question 1 to 28 can be answered with 1: Not at all, 2: A little, 3: Quite a bit, 4: Very much and question 29 to 30 with 1: Very poor to 7: Excellent. For subscales a high score from 0-100 indicates: high global quality of life, high level of functioning (physical, role, emotional, cognitive, social) or a high level of symptoms (fatigue, nausea, pain, dyspnea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties).</description>
        <time_frame>Baseline until EOT (approximately up to 4.7 years)</time_frame>
        <population>The ITT population included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Prednisone 5 mg</title>
            <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Orteronel 400 mg + Prednisone 5 mg</title>
            <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration in Global Health Status</title>
          <description>Global health status deterioration is defined as a drop greater than 16 points from the baseline assessment, confirmed at least 3 weeks later, on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module 30 (EORTC QLQ-C30) index after the score has been linearly transformed to a 0 to 100 scale. EORTC QLQ-C30 consists of 30 questions, where question 1 to 28 can be answered with 1: Not at all, 2: A little, 3: Quite a bit, 4: Very much and question 29 to 30 with 1: Very poor to 7: Excellent. For subscales a high score from 0-100 indicates: high global quality of life, high level of functioning (physical, role, emotional, cognitive, social) or a high level of symptoms (fatigue, nausea, pain, dyspnea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties).</description>
          <population>The ITT population included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="8.97" upper_limit="11.11"/>
                    <measurement group_id="O2" value="8.3" lower_limit="7.36" upper_limit="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (up to Cycle 61 Day 58).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Prednisone 5 mg</title>
          <description>Orteronel placebo-matching tablets, orally, twice daily (BID) and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>Orteronel 400 mg + Prednisone 5 mg</title>
          <description>Orteronel 400 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study. In Japan, participants were administered with Orteronel 300 mg, tablets, orally, BID and Prednisone 5 mg, tablets, orally, BID for up to Day 28 of each treatment cycle throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="380" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cardiotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Secondary adrenocortical insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Thyrotoxic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gallstone ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Tongue abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Radiation proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Post procedural pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urethral stricture postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Eastern Cooperative Oncology Group performance status worsened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to biliary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to small intestine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Metastases to urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gallbladder adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Fibromatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>IIIrd nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Postrenal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Renal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pharyngeal pouch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="721" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="757" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="281" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="784"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="784"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsors confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

